Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells $85,950.00 in Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $11.46, for a total transaction of $85,950.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $10,161,054.84. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $11.24 on Thursday. The company has a 50-day simple moving average of $11.15 and a 200-day simple moving average of $10.61. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75. The stock has a market capitalization of $3.33 billion, a price-to-earnings ratio of -28.82 and a beta of 0.68.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The firm had revenue of $126.67 million during the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The firm’s revenue for the quarter was up 34.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.15) earnings per share. On average, analysts predict that Amicus Therapeutics, Inc. will post -0.06 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Tokio Marine Asset Management Co. Ltd. purchased a new position in Amicus Therapeutics in the third quarter valued at about $113,000. OLD Second National Bank of Aurora purchased a new position in Amicus Therapeutics in the third quarter valued at about $26,000. GSA Capital Partners LLP increased its holdings in Amicus Therapeutics by 163.8% in the third quarter. GSA Capital Partners LLP now owns 133,800 shares of the biopharmaceutical company’s stock valued at $1,429,000 after buying an additional 83,081 shares in the last quarter. Los Angeles Capital Management LLC increased its holdings in Amicus Therapeutics by 46.3% in the third quarter. Los Angeles Capital Management LLC now owns 20,474 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 6,484 shares in the last quarter. Finally, Old West Investment Management LLC increased its holdings in Amicus Therapeutics by 617.2% in the third quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock valued at $3,636,000 after buying an additional 292,976 shares in the last quarter.

Analyst Ratings Changes

FOLD has been the subject of a number of analyst reports. JPMorgan Chase & Co. lowered their target price on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 16th. Bank of America upped their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. Morgan Stanley decreased their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 31st. Finally, Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, August 9th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.13.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.